E7046 (Palupiprant, ER-886046) is a potent, selective, orally bioavailable EP4 receptor antagonist with IC50 of 13.5 nM, Ki of 23.14 nM.
E7046 (Palupiprant, ER-886046) displays >1,500 fold selectivity for EP4 relative to EP4 closest homolog, the PGE2 receptor EP2.
E7046 (Palupiprant, ER-886046) diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.
E7046 (Palupiprant, ER-886046) shows anti-arthritic potential in collagen induced arthritis model.
